At its June 10, 2026 Annual Meeting, Syndax Pharmaceuticals stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP), both effective immediately. The 2026 Equity Incentive Plan reserves 7,200,000 shares of common stock and includes share recycling provisions for expired or cancelled awards from the 2015 Omnibus Incentive Plan. The 2026 ESPP replaces the 2015 ESPP, providing stock purchase rights for both U.S. and foreign employees, though shares from the 2015 ESPP will not roll over. Stockholders also elected directors, ratified the independent auditor, and approved executive compensation. The company is a biopharmaceutical company that develops therapies for cancer and other serious diseases.
